Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

5 treatments under study, led by Bevacizumab

Related Conditions

Often studied with 6 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Phase 2 (1)
Phase 3 (1)

Trial Status

Completed2
Enrolling By Invitation1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT06962449Enrolling By Invitation

Real-World Assessment of Therapeutic Strategies and Survival Outcomes Following First-Line Tislelizumab Therapy in Advanced Non-Small Cell Lung Cancer

NCT04238169Phase 2CompletedPrimary

Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC

NCT01999673Phase 3Completed

Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer

Showing all 3 trials

Research Network

Common Treatments

  • Bevacizumab1
  • Sbrt1
  • Bavituximab1
  • Docetaxel1
  • Toripalimab1

Active Sponsors

  • Xinqiao Hospital of Chongqing1
  • Peregrine Pharmaceuticals1
  • Shanghai Chest Hospital1

Related Conditions

  • Carcinoma Nonsmallcell Lung1
  • Nonsmallcell Lung Cancer1
  • Nonsmallcell Lung Cancer Metastatic1
  • Nonsmall Cell Lung Cancer1
  • Nonsmallcell Lung Cancer Stage Iiib1

Activity Timeline